Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model [0.03%]
新辅助治疗后美国高危HER2阳性早期乳腺癌患者的残留病负荷：一种人群有效性模型
Nathaniel Hendrix,Nina Oestreicher,Deepa Lalla et al.
Nathaniel Hendrix et al.
Background: Approximately half of patients with high-risk HER2-positive early-stage breast cancer (ESBC) do not have pathologic complete response (pCR) after neoadjuvant therapy. The residual burden of disease among this ...
Integrative Expression, Survival Analysis and Cellular miR-2909 Molecular Interplay in MRN Complex Check Point Sensor Genes (MRN-CSG) Involved in Breast Cancer [0.03%]
乳腺癌中MRN复合物检查点传感器基因的整合表达、生存分析及细胞miR-2909分子相互作用研究
Jitender Singh,Namrata Sangwan,Arushi Chauhan et al.
Jitender Singh et al.
Background: Breast cancer, an emerging global challenge, is evidenced by recent studies of miRNAs involvement in DNA repair gene variants (MRE11, RAD50, and NBN as checkpoint sensor genes (CSG) - MRN-CSG). The identificat...
Smoking and Radiation-induced Skin Injury: Analysis of a Multiracial, Multiethnic Prospective Clinical Trial [0.03%]
吸烟诱导的放射性皮炎：一项前瞻性临床多族裔研究分析
Ryan T Hughes,Edward H Ip,James J Urbanic et al.
Ryan T Hughes et al.
Introduction: Smoking during breast radiotherapy (RT) may be associated with radiation-induced skin injury (RISI). We aimed to determine if a urinary biomarker of tobacco smoke exposure is associated with increased rates ...
Multicenter Study
Clinical breast cancer. 2022 Dec;22(8):762-770. DOI:10.1016/j.clbc.2022.09.003 2022
Patient Reported Outcome and Quality of Life After Delayed Breast Reconstruction - An RCT Comparing Different Reconstructive Methods in Radiated and Non-radiated Patients [0.03%]
晚期乳房重建的患者预后和生活质量评估-放射治疗与非放射治疗患者的对比性随机对照试验
Fredrik Brorson,Anna Elander,Andri Thorarinsson et al.
Fredrik Brorson et al.
Background: Health-related quality of life (HRQoL) is one of the core outcomes for breast reconstruction. The aim of this study was to evaluate whether the method of delayed breast reconstruction affects long-term HRQoL. ...
Randomized Controlled Trial
Clinical breast cancer. 2022 Dec;22(8):753-761. DOI:10.1016/j.clbc.2022.09.004 2022
Reena Yadav,Yashwant Kumar,Divya Dahiya et al.
Reena Yadav et al.
Claudin-low breast cancers are recently described entities showing low expression of certain claudins and cell adhesion molecules. Claudins constitute the backbone of tight junctions (TJs) formed between 2 cells. Their dysregulation plays a...
Geriatric Early-Stage Triple-Negative Breast Cancer Patients in Low-risk Population: Omitting Chemotherapy Based on Nomogram [0.03%]
低风险老年早期三阴性乳腺癌患者化疗决策列线图模型的建立及验证
Chen Zhou,Li Xu,Zhenggui Du et al.
Chen Zhou et al.
Background: Considering old age and comorbidities, the actual benefit of chemotherapy in older patients with early triple-negative breast cancer (TNBC) remains uncertain. We aimed to select appropriate patients who could ...
Changes in Spinal Alignment of Women Who Underwent Unilateral Mastectomy with Immediate Autologous Breast Reconstruction Compared To Mastectomy without Breast Reconstruction [0.03%]
单侧乳房切除加即刻自体乳房重建组与单纯乳房切除组女性脊柱排列的变化情况比较研究
Sophia Si Ling Heng,Yin Hui Gan,Maya Mazuwin Yahya et al.
Sophia Si Ling Heng et al.
Introduction: The impact of breast reconstruction on spinal alignment is not well studied, especially in immediate autologous breast reconstruction. Studies on body posture have shown greater asymmetry among those without...
Are We Overtreating Patients With T1a HER2+ Breast Cancer? An Analysis of the National Cancer Database [0.03%]
基于国家癌症数据库对T1a期HER2阳性乳腺癌患者过度治疗的分析
Austin D Williams,Odette Solis,Hélène M Sterbling et al.
Austin D Williams et al.
Introduction: The potential benefit of systemic therapy in patients with T1a HER2+ cancers is not well understood, and no consensus guidelines exist. We sought to investigate practice patterns of chemotherapy use in this ...
Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer [0.03%]
利柏西利与芳香化酶抑制剂一线治疗激素受体阳性、HER2阴性转移性乳腺癌的现实世界预后研究
Vanessa Wong,Richard de Boer,Sally Baron-Hay et al.
Vanessa Wong et al.
Background: International guidelines recommend combining a CDK4/6 inhibitor and endocrine therapy (ET) as first line treatment for hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC). Results from...
A Randomized Controlled Phase 2 Study of Neoadjuvant Eribulin Versus Paclitaxel in Women with Operable Breast Cancer: The JONIE-3 Study [0.03%]
新辅助厄洛替尼与紫杉醇治疗可手术乳腺癌的II期随机对照研究：JONIE-3研究
Kazutaka Narui,Daishu Miura,Yoshie Hasegawa et al.
Kazutaka Narui et al.
Objective: Neoadjuvant chemotherapy (NAC) is essential for surgical downstaging of early-stage breast cancer, but taxane administration is associated with neuropathy. We investigated whether eribulin induces less neuropat...
Clinical Trial
Clinical breast cancer. 2022 Dec;22(8):e881-e891. DOI:10.1016/j.clbc.2022.08.007 2022